Anúncio
Anúncio
BMRN
BioMarin Pharmaceuticals Inc
61.28
USDPatrocinado
+1.21
+2.02%
07 de jan., 16:00 UTC -5
Encerrado
Pós-Mercado
61.03
-0.25
-0.41%
Relatórios de Lucros BMRN
Rácio de surpresa positiva
BMRN separação 29 de 40 últimas estimativas.
73%
Próximo Relatório
Data do Próximo Relatório
17 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$838.15M
/$0.86
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+7.99%
/-637.50%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+12.16%
/+34.38%
BioMarin Pharmaceuticals Inc earnings per share and revenue
On 27 de out. de 2025, BMRN reported earnings of -0.16 USD per share (EPS) for Q3 25, missing the estimate of 0.37 USD, resulting in a -142.18% surprise. Revenue reached 776.13 milhão, compared to an expected 796.24 milhão, with a -2.53% difference. The market reacted with a +1.56% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 27 analistas forecast an EPS of 0.86 USD, with revenue projected to reach 838.15 milhão USD, implying an diminuir of -637.50% EPS, and aumentar of 7.99% in Revenue from the last quarter.
FAQ
What were BioMarin Pharmaceuticals Inc's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, BioMarin Pharmaceuticals Inc reported EPS of -$0.16, missing estimates by -142.18%, and revenue of $776.13M, -2.53% below expectations.
How did the market react to BioMarin Pharmaceuticals Inc's Q3 2025 earnings?
The stock price moved up 1.56%, changed from $52.67 before the earnings release to $53.49 the day after.
When is BioMarin Pharmaceuticals Inc expected to report next?
The next earning report is scheduled for 17 de fev. de 2026.
What are the forecasts for BioMarin Pharmaceuticals Inc's next earnings report?
Based on 27
analistas, BioMarin Pharmaceuticals Inc is expected to report EPS of $0.86 and revenue of $838.15M for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio